On August 26, 2026, Zacks Investment Research featured Iovance Biotherapeutics as one of five biotech stocks recommended for portfolios. The report highlighted Iovance's development of tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. It also noted the strong performance of its lead product, Amtagvi.
Amtagvi is the first approved treatment for advanced melanoma that has progressed after prior anti-PD-1 therapy. Zacks expects the drug's sales momentum to continue, driven by increasing patient enrollments.
This demand has also boosted sales of Proleukin, which is used in conjunction with the Amtagvi regimen. The analysis points to Iovance's commercial execution and potential for continued growth in the oncology market.